Menu Back toTOPIC-2-SESSION-1-CONTINUED-SUSAR-Reporting-in-Clinical-Trials-and-Case-Studies

Joint MHRA/DIA Excellence in Pharmacovigilance

This course is designed to provide a firm grounding in key aspects of European Clinical Pre- and Post-Marketing Safety regulatory requirements.


TOPIC 2 SESSION 1 CONTINUED: SUSAR Reporting in Clinical Trials and Case Studies

Session Chair(s)

Gaby L. Danan, MD, PhD

Gaby L. Danan, MD, PhD

  • Pharmacovigilance Expert
  • GLD, France
Phil  Tregunno

Phil Tregunno

  • Group Manager, Vigilance, Intelligence and Research Group
  • Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

Speaker(s)

Gaby L. Danan, MD, PhD

SUSAR Reporting in Clinical Trials and Case Studies

Gaby L. Danan, MD, PhD

  • Pharmacovigilance Expert
  • GLD, France

Contact us


Registration Questions

Send Email
+41 61 225 51 51



Agenda and Logistics

Send Email
+41 61 225 51 55